Jun 16, 2021
RNS Number : 0186C MaxCyte, Inc. 16 June 2021                                     MaxCyte, Inc. (" MaxCyte " or the "Company")   Publication of Annual Report and Accounts   Gaithersburg, Maryland - 16 June 2021 : MaxCyte (LSE: MXCT, MXCN), a leading provider of cell-engineering platform
Jun 16, 2021
RNS Number : 0185C MaxCyte, Inc. 16 June 2021         Publication of Stockholder Circular and Notice of Special Meeting     Gaithersburg, Maryland - 16 June 2021 :   MaxCyte (LSE: MXCT, MXCN), a leading provider of platform technologies for cell engineering, today announced that it has published a
Jun 15, 2021
RNS Number : 8666B MaxCyte, Inc. 15 June 2021         MaxCyte Adds Two New Non-Executive Directors to Its Board   Gaithersburg, Maryland - 15 June 2021 :   MaxCyte (LSE: MXCT, MXCN), a leading provider of platform technologies for cell engineering, today announced the appointment of Rekha Hemrajani
Jun 02, 2021
RNS Number : 5575A MaxCyte, Inc. 02 June 2021       MaxCyte, Inc. (" MaxCyte " or the "Company")   Total Voting Rights     Gaithersburg, Maryland - 2 June 2021 :   MaxCyte (LSE: MXCT, MXCN), the global cell-based medicines and life sciences company, announces that pursuant to its block admission
May 25, 2021
RNS Number : 6449Z MaxCyte, Inc. 25 May 2021       FOR IMMEDIATE RELEASE   Celularity and MaxCyte Sign Strategic Platform Licence to Advance Celularity's Off-the-shelf Allogeneic Cellular Therapy Product Candidates   Celularity to utilize MaxCyte's Flow Electroporation ® technology and ExPERT ™
May 14, 2021
RNS Number : 6562Y MaxCyte, Inc. 14 May 2021   Proposed Dual-Listing on Nasdaq   This announcement contains inside information     Gaithersburg, Maryland -   May   14, 2021 - MaxCyte, Inc. (LSE: MXCT, MXCL, MXCN) (" MaxCyte " or the " Company "), a leading provider of platform technologies for cell
May 13, 2021
RNS Number : 4604Y MaxCyte, Inc. 13 May 2021       NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.   THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR
Apr 20, 2021
RNS Number : 9571V MaxCyte, Inc. 20 April 2021   MaxCyte, Inc. (" MaxCyte " or the "Company")   MaxCyte Reports Final Results for the Year Ended 31 December 2020   Gaithersburg ,   Maryland   - 20   April   2021:     MaxCyte   (LSE:   MXCT, MXCL, MXCN), a leading provider of cell-engineering
Apr 15, 2021
RNS Number : 5163V MaxCyte, Inc. 15 April 2021                                     MaxCyte, Inc. (" MaxCyte " or the "Company")   Notice of Full Year Results   Gaithersburg, Maryland - 15 April 2021 : MaxCyte (LSE: MXCT, MXCL, MXCN), a leading provider of cell-engineering platform technologies for
Apr 01, 2021
RNS Number : 2232U MaxCyte, Inc. 01 April 2021       MaxCyte, Inc. (" MaxCyte " or the "Company")   Total Voting Rights     Gaithersburg, Maryland - 1 April 2021 :   MaxCyte (LSE: MXCT, MXCL, MXCN), the global cell-based medicines and life sciences company, announces that pursuant to its block
Displaying 41 - 50 of 67